Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Phase III DESTINY-Breast03 trial (NCT03529110) comparing the efficacy and safety of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer who had received at least one prior anti-HER2 regimen. The updated results, with a median follow-up of 43.0 months for T-DXd and 35.4 months for T-DM1, show a clinically meaningful improvement in overall survival (OS), progression-free survival (PFS), and PFS on next line of therapy (PFS2) with T-DXd. Notably, the safety profile of T-DXd remains manageable, with no cumulative toxicities observed over longer follow-up. These findings reinforce the superiority of T-DXd over T-DM1 as a treatment option for HER2-positive metastatic breast cancer. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.